DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

Togami, Katsuhiro

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. [electronic resource] - The Journal of clinical investigation 11 2019 - 5005-5019 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1558-8238

10.1172/JCI128571 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Azacitidine--pharmacology
Cell Line, Tumor
DNA Methylation
Dendritic Cells--metabolism
Drug Delivery Systems
Female
Hematologic Neoplasms--drug therapy
Humans
Interleukin-3 Receptor alpha Subunit--metabolism
Leukemia, Myeloid, Acute--drug therapy
Male
Mice
Mice, Nude
Minor Histocompatibility Antigens--metabolism
Neoplasm Proteins--metabolism
Recombinant Fusion Proteins--pharmacology
Tumor Suppressor Proteins--metabolism
Xenograft Model Antitumor Assays